The identification of novel negative allosteric modulators of the nicotinic recep

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$190,807.00
Award Year:
2009
Program:
STTR
Phase:
Phase I
Contract:
1R41DA026245-01
Award Id:
93627
Agency Tracking Number:
DA026245
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
PROMILIAD BIOPHARMA, INC, ALBERTON, MT, 59820
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
130194082
Principal Investigator:
DENNIS MCKAY
(614) 292-3771
MCKAY.2@OSU.EDU
Business Contact:
DANA WARREN
() -
dana.e.warren@mail.promiliad.com
Research Institution:
OHIO STATE UNIVERSITY

Office of Sponsored Programs
1960 Kenny Road
COLUMBUS, OH, 43210-2340

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma w ith the expertise of Professor Dennis McKay to identify novel and subtype selective negative allosteric modulators of the nicotinic acetylcholine receptor. We believe that such compounds could provide a significant improvement in available therapies for sm oking addiction. Work supported with this grant will examine the Promiliad Biopharma compound database to identify small molecules that fit a previously identifed nicotinic acetylcholine receptor pharmacophore. Compounds that fit the pharmacophore will be examined in a variety of pharmacological assays to identify negative allosteric modulators of three subtypes of the nicotinic acetylcholine receptor. In addition to the in silico screening of the Promiliad compound library, Promiliad Biopharma will prepare libraries of previously identified negative allosteric modulators of the nicotinic acetylcholine receptor. These libraries will make use of Promiliad's drug discovery technology in order to prepare a diverse and novel set of analogues. In addition to iden tifying a new selective negative allosteric modulator of the nicotinic acetylcholine receptor, this project will also allow Promilad to test the hypothesis that the Promiliad drug discovery technology can be used for the idenfication of a variety of therap eutic agents. PUBLIC HEALTH RELEVANCE: The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma with the expertise of Professor Dennis McKay to identify novel and subtype selective negative allosteric modulators of the nicotinic acetylcholine receptor. We believe that such compounds could provide a significant improvement in available therapies for smoking addiction.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government